The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 597 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These 597 APIs account for 4,229 approved ANDAs.
Including all approved doses, the current universe of generic solid dosage forms consists of 9,687 unique tablet and capsule products. These products are marketed and supplied by more than 800 companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.
Generic Solid Dosage Forms - What You Will Learn:
Provides detailed analysis of generic drugs supplied as solid dosage forms and assesses key market segments, market dynamics and potential product opportunities
Presents the competitive picture for generic tablets and capsules in two dozen drug classes
Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
Assesses the market presence and product position of the top twenty-four generic suppliers in the solid dosage form segment
Evaluates the impact of economic, technology, and regulatory factors